Revolution in the OR: New Alliance Targets Cancer Reoperations
- A New Dawn in Cancer Care: Perimeter Medical Imaging AI (TSXV: PINK, OTCQX: PYNKF) joins forces with healthcare titan Intermountain Health.
- Targeting Reoperations: Their mission: to dramatically reduce the need for repeat cancer surgeries using advanced OCT imaging and AI.
- Hope for Patients: Initial focus on breast cancer aims to lessen patient trauma, improve outcomes, and cut healthcare costs3, 5.
In the fight against cancer, the words "we need another operation" can be devastating. Now, a groundbreaking partnership aims to silence those words for countless patients. Perimeter Medical Imaging AI, Inc., a pioneer in medical technology, is teaming up with Intermountain Health, one of America's leading nonprofit health systems6, to tackle the pervasive issue of cancer reoperations.
This powerful alliance will study the potential of Perimeter's cutting-edge Optical Coherence Tomography (OCT) combined with artificial intelligence to ensure surgeons can "see the unseen" during initial cancer surgeries. The goal is to achieve clean margins in real-time, drastically reducing the need for patients, particularly those undergoing breast-conserving surgery, to endure the physical, emotional, and financial toll of follow-up procedures3, 5.
Intermountain Health, with its vast network and commitment to innovation6, 8, provides the perfect proving ground. Their first joint study will retrospectively analyze reoperation rates and costs, feeding invaluable data into Perimeter's AI algorithms4. "We understand the significance of innovation...that has the potential to optimize surgical oncology outcomes," stated an Intermountain Health medical director.
Perimeter's CEO highlighted Intermountain's unique position to evaluate the total cost of reoperations. This collaboration isn't just about technology; it's about reshaping patient experiences and forging a new, more efficient path in cancer treatment, potentially expanding beyond breast cancer to other tissue types in the future.
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.